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Significance for Public Health 
Immunization and control of diseases in the process of elimination, such as neonatal tetanus and 
with a recent resurgence such as diphtheria and pertussis constitute a challenge for Colombia, the 
region, and the world. The impact of infant and maternal vaccination on reducing the incidence of 
diphtheria, tetanus, and pertussis in Colombia, has been reported in this study. Childhood and 
maternal vaccination markedly reduced the incidence of neonatal pertussis and tetanus. The change 
in incidence of diphtheria was significant before and after immunization, although slow. Public 
health efforts should focus on improving and sustaining maternal and child vaccination against 
diphtheria, tetanus and pertussis. Development of an integrated elimination plan is recommended 
for the three diseases based on the experience of neonatal tetanus. 
 
Abstract 
Background: In Latin America, there are few studies of the impact of vaccination against 
diphtheria, tetanus, and pertussis. We estimate the impact of infant and maternal vaccination on 
the incidence of these diseases in Colombia. 
Design and methods: an interrupted time series study analyzing the incidence before and after of 
vaccination with DwPT (1975-2018) and with Tdap in pregnant women (2008-2018). A segmented 
regression model with negative binomial distribution estimated the change in level and trend of the 
predicted incidence ratio after vaccination in relation to the incidence if vaccination had not been 
started (IRR), using a Prais Winsten regression.  
Results: The pertussis IRR decreased immediately after the start of childhood vaccination (0.91, 
p=0.51), but this was only significant (1.01, p<0.001) along with the trend per year, after the start 
of maternal vaccination (0.98, p<0.001). In the absence of vaccination, the incidence would not have 
been reduced. Neonatal tetanus had the highest rate of change with significant reduction -1.69 - CI 
95%: -2.91, -0.48). The trend after vaccination was the highest with an annual reduction of 19% 
(0.81, p=0.001). The change in incidence of diphtheria was significant, although slow (-0.02 - CI 
95%: -0.04, -0.004). The sustained effect in the post-vaccination period was smaller (0.95, p=0.79). 




neonatal tetanus. It is necessary to maintain optimal vaccination coverage and surveillance, within 
an integrated elimination plan, which prevents the resurgence of these diseases. 
 
Key words: Incidence; immunization programs; interrupted time series analysis; diphtheria-
tetanus-pertussis vaccine.  
 
Introduction 
The COVID-19 pandemic has reminded humanity not only of the need to anticipate the 
development of technologies for new vaccine creation, but also the urgency of increasing access 
and coverage of vaccines that have been available for more than a century.1 The resurgence of 
diphtheria, neonatal tetanus, and pertussis is a global concern following the mortality from 
diphtheria in unvaccinated children in Peru during the COVID-19 pandemic2, the resurgence of 
pertussis in the last decade 3, and concern about the loss of progress in neonatal tetanus 
elimination.4 
In Latin America there are few studies of the impact of vaccination. In Colombia; despite having 
an Expanded Program of Immunizations (EPI) since the mid-70s 5, few have studied the temporal 
behavior of these diseases. In Argentina 6 and Colombia, the impact of maternal vaccination with 
Tdap on the burden of pertussis was analyzed through descriptive studies of incidence and 
mortality 7, seroprevalence studies8, documentation of the neonatal tetanus elimination process 
from 1989 to 2005 9, cost-benefit analysis of booster tetanus vaccination in adults10, and description 
of a diphtheria outbreak reported in 2000. 11 
In Colombia, childhood vaccination against diphtheria, tetanus, and pertussis (DwPT) began in 
1980 through the EPI using a three-dose schedule (2, 4 and 6 months of age). 5,12 In 1996, two 
reinforcements were added at 18 months and 5 years. In 1990, vaccination with tetanus and 
diphtheria toxoid (Td) was initiated for women of childbearing age between 10 and 49 years to 
prevent diphtheria and neonatal tetanus. 5,12 Following the resurgence of pertussis in 2013, 
vaccination of pregnant women with acellular pertussis vaccine (Tdap) was introduced. 13 The 
maternal and neonatal tetanus elimination plan began in 1989 including vaccination with tetanus 
toxoid, improved surveillance, and promotion of safe delivery through umbilical cord care. 9  
This work seeks to quantify the population impact of vaccination against diphtheria, tetanus, and 




(2008-2012) and after (2013-2018) maternal vaccination with acellular vaccine (Tdap) by 
analyzing the temporal change in incidence in Colombia. 
The baseline provided in this study can be informative for decision makers, in the country and the 
region, to compare the incidence in the future and achieve prioritization of these vaccines so that 
no one else suffers from these diseases in the 21st century. 
 
Design and Methods 
This is a retrospective study of secondary sources that estimates the impact of childhood and 
maternal vaccination against diphtheria, tetanus, and pertussis by means of an interrupted time 
series analysis14 with segmented regression to determine the change in magnitude and trend of 
incidence before and after the start of vaccination. 
 
Data Sources 
The confirmed cases of these diseases were reported to the national epidemiological surveillance 
system "SIVIGILA",15 whose notification is mandatory and standardized, following criteria 
defined by the National Institute of Health of Colombia (INS, or Instituto Nacional de Salud de 
Colombia in Spanish).15 The time series comprised the period from 1973 for diphtheria16,17 and 
from 1975 for all forms of tetanus and pertussis.16,18 The neonatal tetanus analysis included annual 
data from 1981 to 2018.16,19 The effect of the Tdap vaccine was analyzed with weekly pertussis 
data reported from 2008 to 2018. 
Data on vaccination coverage were obtained from the databases of the Ministry of Health and 
Social Protection of Colombia.20 This information was supplemented with other government 
publications.16 The population denominators were obtained from the official databases of the 
National Administrative Department of Statistics (DANE, Departamento Administrativo Nacional 
de Estadística in Spanish).21 
 
Statistical analysis 
The interrupted series analysis determined the incidence level of the three diseases in each segment 
analyzed before and after the start of vaccination. The slope indicated the decreasing, ascending, 
or stable trend of the series. Changes in level indicated an immediate effect while changes in slope 




The analysis included: a) Data cleaning b) Descriptive analysis of the temporal behavior of 
incidence, vaccination coverage, and characteristics of cases reported in the resurgence period of 
the three diseases. The rate of change and the dependence of the incidence rates per year were 
calculated (the rate of a given year depends on what happened in the immediately previous year) 
through a Prais Winsten regression,22,23 c) Estimation of the series parameters using a segmented 
regression model with negative binomial distribution, d) Evaluation of the seasonal component in 
the 2008-2018 pertussis series, e) Estimation of the percentage reduction in the relative incidence 
IRR (ratio of the incidence predicted after of vaccination in relation to incidence if vaccination had 
not been started). 14,22-24 
The segmented regression model was as follows: 
 
!! = #" + ## ∗ &'()! + #$ ∗ *&+,&	./	0+11'2+&'.2! + #% ∗ &'()	+/&),	0+11'2+&'.2	! + )! 
 
Where !! is the relative incidence IRR at time t,  #" is the intercept or baseline of IRR at the 
beginning of the series. Time was coded as 0 (before vaccination) and 1 (after vaccination) 25. ## 
estimates the change in IRR level before the start of vaccination. #$ estimates the immediate effect 
or change in the IRR level immediately after the start of vaccination (at the end of the prevalence 
period). #% estimates the sustained effect, or change in trend, in IRR per unit time after the start of 
vaccination compared to the previous trend. )!	is the random variability not explained by the 
model. 
The time unit for the analysis of the impact of childhood vaccination was annual and that of 
maternal vaccination was weekly. 
Data were analyzed with Stata ® (version 14. Statistical Software: StataCorp LLC, College Station, 
Texas, United States). 
 
Ethical approval 
This study was approved by the ethics committee of the “Héctor Abad Gómez” National School 
of Public Health of the University of Antioquia (session 204 of February 1, 2019, CEI Code 021-
2019). It used anonymous data from official sources. The manuscript does not contain any 






Vaccination coverage against DwPT increased gradually from the beginning of the EPI until the 
1990s. Then, coverage varied, with a predominance of estimates lower than 80%, being lower 
between 1998-2000 (73-79%), and above 85% since 2003 (Figure 1). 
Tdap vaccination coverage in pregnant women increased from 72% in 2013 to 92% in 2018. 
The reported cases per 100 000 inhabitants of the three diseases decreased considerably even before 
the start of vaccination and more markedly until the 1980-1990s, with variations by disease. 
The incidence of diphtheria gradually decreased until 1990 when there was a resurgence of cases 
between 1990-1995 and then in 2018 when eight cases were reported, all imported from Venezuela. 
The cases were men of different ages (one case was 3 years old, three cases were between 4 and 
17 years old, two cases were between 18-29 years old, and two cases were between 30 and 40 years 
old), 75% (n = 6 / 8) were hospitalized and 37.5% (n = 3/8) died. 
Tetanus of all forms, like neonatal tetanus, was progressively reduced from 1980 to 1995, 
subsequently observing a sustained decrease in incidence. Between 2008 and 2018, 28 cases of 
neonatal tetanus were reported. The cases had an average age of 14 days (SD ± 7) of these cases 
64.3% (18/28) belonged to the urban area and 17.8% (5/28) to the rural area. Of those reported, 
67.85% (19/28) were hospitalized and 25% (7/28) died. 
The incidence of pertussis decreased gradually until 1995 when it maintained a low incidence and 
then increased after the resurgence reported between 2011 and 2013 (Figure 1). Of the 14 809 
cases reported between 2008 and 2018, 71% (n = 10 519) occurred between 2011 and 2013, around 
65% of the cases were reported in children under one year of age, especially those under two 
months. In the epidemic period from 2011 to 2013, the mean age and percentage of cases in those 
older than three years increased, compared to other periods. The time between onset of symptoms 
and health services visits was shorter during the epidemic period. After the start of maternal 
vaccination in 2014-2018, an increase in rural, hospitalized, and deceased cases was observed. 
Confirmation of pertussis was predominantly carried out by laboratory, except in the epidemic 
period when clinical confirmation increased. After the epidemic period in which maternal 
vaccination began, laboratory confirmation of cases was lower compared to the pre-epidemic 
period (Table 1). 
As shown in Table 2, the maximum incidence range was higher for pertussis and neonatal tetanus 




rate of change shows a significant reduction for diphtheria and neonatal tetanus, with 2 000 and 
169 000 cases annually, respectively. The rate of change of pertussis was more evident after 
maternal vaccination began, although not significant, and presented the highest dependence of 
incidence rates between years (correlation of 0.91) (Table 2). 
Table 3 shows the magnitude of change in IRR for the three diseases. The mean predicted rate 
before the start of vaccination compared to the mean predicted rate at baseline (β1) decreased (1-
IRR), for diphtheria in 14%, pertussis in 9%, neonatal tetanus in 4%, and all forms of tetanus in 
3%. 
The immediate effect (β2) in IRR for all diseases ranged between 25% and 78%, although this effect 
was statistically significant only for pertussis and neonatal tetanus (Figure 2). 
Regarding the sustained effect (β3) of the intervention, an annual reduction in IRR of 19% was 
observed for neonatal tetanus, 15% for all forms of tetanus, 5% for diphtheria, 2% for pertussis 
after infant and maternal vaccination (Table 1). 
Figure 2 shows that, if the vaccination program had not been implemented, the diphtheria rate 
would have a similar magnitude between what was reported and what was predicted (29 vs 31). 
All forms of tetanus (63 vs 74) and neonatal tetanus (20 vs 13) show marked incidence rate 
reductions. Pertussis would have had an increased incidence rate if vaccination had not been 
implemented (20 vs 12) (Figure 2). 
 
Discussion 
This study detected the reduction in temporal trend in diphtheria, tetanus, and pertussis incidence 
more markedly after the introduction of vaccination with DwPT in 1980 and Tdap in 2013. 
Vaccination coverage with DwPT increased gradually since 1980, but was below 80% between 
1998-2002, possibly related to the shortage of biologicals and the reorganization of the provision 
of health services after the reform of the Colombian health system 5,26, a situation that may be more 
critical in some municipalities due to disparities in vaccination coverage.27 Although maternal 
vaccination coverage increased gradually in 2018, in 2020 it presented a global figure of less than 
80%, after the COVID-19 pandemic.20  
This study estimated that pertussis incidence would not have been reduced if there had not been 
massive vaccination of children and significant maternal vaccination. However, it is necessary to 




due to the resurgence observed between 2011-2013, the low trend magnitude after maternal 
vaccination compared to the pre-vaccination period, and the high per year correlation of annual 
incidence dependence. 
The resurgence of pertussis reported worldwide has been explained by different factors including 
the loss of vaccine immunity over time and the reduction in vaccination coverage.28,29 Although 
the effectiveness of maternal vaccination has been widely studied,8,30,31 there is a need to strengthen 
epidemiological surveillance of pertussis and develop new approaches based on hospital reporting, 
to avoid late consultation, complications, and death. In our study, a percentage increase in 
hospitalization and mortality, higher frequency of cases in the dispersed rural area, and lower 
laboratory confirmation of cases were observed after the epidemic period compared with the 
epidemic period. The characteristics of pertussis cases reported during the resurgence in Colombia 
were similar to those in published works 32 in terms of the higher frequency of cases in children 
under two months of age and the occurrence of cases in adolescents and adults, whose atypical 
symptoms make diagnosis difficult.  
The observed impact of vaccination on pertussis incidence is similar to that reported in several 
studies. In Colombia, a study evaluated the effect of maternal vaccination on pertussis incidence 
and mortality in children under one year of age in Bogotá D.C., using data from the surveillance 
system-notified cases, and found a reduction between 54 and 87.5% of the cases in the different 
age groups. In Argentina 6 authors estimated the impact of the maternal acellular pertussis vaccine 
in reducing the burden of childhood morbidity using data from the surveillance system, taking into 
account areas with high and low Tdap coverage and comparing the incidence before and after 
vaccination. These authors reported a 51% relative reduction (95% CI: -67%, -35%; p =0.001) in 
the incidence of pertussis, in areas where vaccination coverage was high.6 In China, authors 
reported a significant reduction in diphtheria, tetanus, and pertussis incidence just after the 
implementation of the DwPT vaccination program.32 
With respect to diphtheria, a greater reduction in incidence was observed even before the start of 
vaccination, which could be related to the improvement of socioeconomic conditions of the 
population. After the start of vaccination, a significant, albeit slow, change in incidence was 
observed between the pre- and post-vaccination period. The sustained effect on incidence in the 
post-vaccination period was modest and not significant. 




resurgence of cases in 2018 in Colombia and other Latin American and Caribbean countries, 
concerns have been raised about the reemergence of this and other vaccine-preventable diseases 
due to population displacement and the inability to sustain optimal vaccination coverage in both 
migrant and recipient populations. New approaches such as identification of susceptible groups 
through seroprevalence studies and intensification of vaccination and epidemiological surveillance 
in populations in social conflict and with limited access to health services are needed to avoid cases 
occurrence.33 
The incidence of neonatal tetanus presented the most notable reduction in level and trend after the 
start of vaccination, which coincides with other authors who showed a 94% reduction in neonatal 
tetanus incidence in Colombia from 1989 to 2005.10  The detected effect could be due to vaccination 
reinforcement with integrated measures of surveillance and umbilical cord care within the maternal 
and neonatal elimination plan.34 
This study has several limitations. It was not possible to have the incidence data for 2019-2020 as 
it is in the process of being updated, nor the monthly incidence data and vaccination coverage 
before the start of the EPI. These data, like census information, are permanently reviewed by the 
country's health and demographic authorities and in this work, they were refined and contrasted 
with different sources of information, using official figures. 
In conclusion, childhood and maternal vaccination markedly reduced the incidence of neonatal 
pertussis and tetanus in Colombia. 
Development of an integrated elimination plan is recommended for the three diseases based on the 
experience of neonatal tetanus. In this plan, ensuring the stability of vaccination program health 
and workers should be a priority along with epidemiological surveillance that allows maintaining 
optimal vaccination coverage, continuously monitoring the behavior of the diseases, developing 
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Table 1. Demographic and clinic features of the cases of pertussis in Colombia from 2008 to 2018. 
Variable 2008-2010 2011-2013 2014-2018 Total  
Age: mean (min-max) 3.8 (0-86) 5.2 (0.1- 88) 3.3 (0.1- 84) 4.9 (0.1- 88.9) 
Symptom onset and consultation: 
average (min-max) 
5.4 (1-54) 3.5(2 - 48) 4.4 (1-51) 4.2 (1- 54) 
  n (%) n (%) n (%) n (%) 
Age 
 
   
<2 months 442 (37.46) 3900 (37.08) 1303 (41.89) 5645 (38.11) 
2-6 months 244 (20.68) 1951 (18.55) 771 (24.79) 2966 (20.02) 
6-12 months  51 (4.32) 688 (6.54) 261 (8.39) 1000 (6.75) 
>1-3 years 289 (24.49) 1361 (12.94) 443 (14.24) 2093 (14.13) 
4-6 years 42 (3.56) 518 (4.92) 61 (1.96) 621 (4.19) 
7-14 years 54 (4.58) 840 (7.99) 88 (2.82) 982 (6.6) 
15-89 years 58 (4.92) 1261 (11.99) 183 (5.88) 1502 (10.14) 
Gender 
 
   
Female 587 (49.75) 5269 (50.09) 1570 (50.48) 7426 (50.14) 
Male 593 (50.25) 5250 (49.91) 1540 (49.51) 7383 (49.85) 
Area 
 
   
City center 1003 (85.00) 8783 (83.50) 2463 (79.19) 12249 (82.71) 
Countryside 94 (7.97) 727 (6.91) 262 (8.42) 1083 (7.13) 
Rural area 83 (7.03) 1009 (9.59) 385 (12.37) 1477 (9.97) 
Hospitalization         
Yes 322 (27.29) 6421 (61.04) 2462 (79.16) 9205 (62.15) 
No 858 (72.71) 4098 (38.96) 648 (20.83) 5604 (37.84) 
Mortality     
Yes 16 (1.36) 161 (1.53) 63 (2.02) 240 (1.62) 
No 1164 (98.64) 10356 (98.45) 3046 (97.94) 14566 (98.35) 
Laboratory-confirmed cases 930 (78.81) 4776 (45.40) 1834 (67.88) 7542 (52.36) 
Confirmed by clinical  104 (8.81) 4532 (43.08) 843 (31.20) 5479 (38.05) 






















Speed of change 
per year  




Diphtheria  1973 – 1980 1980 – 2018 0.67 - 2.90 0 - 0.49 -0.02 
(-0.04; 0.004)* 
0.59 
Tetanus all forms 1975 – 1980 1980 – 2018 1.87- 2.44 0.02- 2.65 -0.03 
(-0.08; 0.03) 
0.89 
Neonatal tetanus 1980 – 1989 1989 – 2018 15.23 -75.3 0.26-15.8 -1.69 
(-2.91; -0.48* 
0.76 
Pertussis (DwPT) 1975 – 1980 1980 – 2018 44.1 - 72.9 0.10- 28.5 0.15 
(-0.56; 0.86) 
0.87 
Pertussis (Tdap) 2008 – 2013 2013 – 2018 0.1 - 32.8 0.03- 62.2 -0.19 
(-0.61; 0.24) 
0.91 






Table 3. Interrupted time series (ITS) based on the trends of diphtheria, tetanus and pertussis incidence rates, Colombia. 
 
Diseases/vaccine Terms of the model IRR p-value 95% CI 
Diptheria 1973-2018  
Slope of the line before immunization (β1) 0.86 0.274 0.66 - 1.13 
Sustained effect (β3) 0.95 0.797 0.66 – 1.37 
Tetanus all forms 1975-2018  
Slope of the line before immunization (β1) 1.03 0.862 0.75 – 1.41 
Sustained effect (β3) 0.85 0.327 0.61 – 1.18 
Neonatal tetanus 1981-2018  
Slope of the line before immunization (β1) 1.04 0.526 0.93 – 1.15 
Sustained effect (β3) 0.81 0.001 0.72 – 0.91 
Pertussis 1975-2018 
Slope of the line before immunization (β1) 0.91 0.518 0.67 – 1.22 
Sustained effect (β3) 0.98 0.901 0.72 – 1.33 
Maternal 2008-2018 Slope of the line before immunization (β1) 1.01 <0.001 1.01 – 1.02 









Figure 1. Number of new cases per 100 000 inhabitants notified of diphtheria, all forms tetanus, 
























































































































































































































































Figure 2. Reported and predicted incidence of the diphtheria, tetanus and pertussis with 
interrupted time series analysis, Colombia 
 
